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 Editorial
Procalcitonin direct antibiotic therapy in immunocompromised patients
Procalcitonin (PCT) is a prohormone produced by the C-cells of the 
thyroid. Once split it becomes calcitonin and is responsible for calcium 
homeostatic. In response to pro-inflammatory cytokines extrathyroidal 
nonendocrine tissue produces immature PCT which can be detected in 
the circulation, reaching a maximum within approximate 12–24 hours 
after the onset of inflammation. Uniquely, interferon-gamma, which is 
released during viral infections, inhibits the production of PCT thereby 
making elevations in PCT useful in detecting bacterial infections as 
opposed to viral infections.1 Despite these potential benefits the role of 
PCT in the intensive care unit (ICU) has not been fully established. The 
problem is that PCT elevations can take place because of non-infective 
systemic inflammation, as seen during major trauma or after cardiac 
bypass, thereby making it difficult to differentiate bacterial from non-
bacterial causes.2 This, together with the 24–48 hour time lag after the 
onset of an infection, as well as the persistent elevation seen after a 
major episode of systemic inflammation, limits the diagnostic accuracy 
of PCT. 
Despite these limitations the use of PCT algorithms to direct antibiotic 
duration and discontinuation in ICU patients has shown great success 
reducing the number of patients receiving antibiotics as well as 
shortening antibiotic duration.3 Interestingly, a recent individual patient 
meta-analysis found that in the 2252 patients who received PCT-
guided therapy, the morality rate was 21.1% as opposed to 23.7% in the 
2230 patients who received standard of care (adjusted odds ratio 
0.89, 95% CI 0.8 to 0.99; p=0.03). In addition, those who were in the PCT 
arm had their antibiotics discontinued earlier than the control arm.4 PCT 
clearly has a role to play here and has been widely adopted in many 
local ICUs. 
However, all these trials excluded patients with severe immuno-
compromise and as a result there is very little data to guide PCT use 
in this subpopulation. It is into this gap that the paper by Naidoo and 
colleagues speaks.5 In their study, conducted at a tertiary level intensive 
care unit (ICU) in KwaZulu-Natal, they examined the relationship 
between PCT and ICU morality, length of stay, and ventilation duration 
in patients admitted to ICU with a diagnosis of community acquired 
pneumonia. As a secondary outcome, they explored the ability of 
PCT to predict aetiology as well as organ dysfunction. Out of the 
100 patients enrolled in the study 62% were HIV positive and had 
a median CD4 count of 64 cell/µL. A PCT elevated >  10 ng/ml was 
predictive of a higher morality than those in whom the PCT decreased 
or remained unchanged and was also associated with a greater need for 
inotropic support and acute renal failure.5 
The study was well conducted with a good yield on formal 
microbiological cultures and in a population with profound respiratory 
impairment.5 This provides us with real-world practical data on how PCT 
performs in a South African population and highlights the wide variety 
of microorganisms causing community acquired pneumonias in our 
ICUs. A concern in this study is the use of repeated univariate testing 
without p-value correction, which may have increased the risk of false 
positives. It may have been more appropriate to conduct a logistic 
regression analysis with multiple predictors to both spare power and to 
understand the strength of the association with PCT in the presence of 
other risk factors.5 
What is striking in this study was that there was no association between 
admission or 48hour PCT categories and the microorganisms cultured, 
except in those with a PCT > 10 ng/ml where there was a higher 
incidence of bacterial infections.5 This raises a concern that the PCT 
directed antibiotic guidelines and their thresholds which have been 
developed in different study populations may not be relevant in an ICU 
population such as this. This study has clearly identified a gap in our 
understanding of PCT kinetics in immunocompromised patients and 
can serve as a great starting point from which to further explore this 
question. The authors are to be congratulated on taking this important 
first step.
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